Obesity is a low grade inflammatory state associated with premature cardiovascular
morbidity and mortality. Along with traditional risk factors the measurement of endothelial
function, insulin resistance, inflammation and arterial stiffness may contribute to the
assessment of cardiovascular risk. We conducted a randomised placebo controlled trial to
assess the effects of 12 weeks treatment with a PPARα agonist (fenofibrate) and a PPARγ
agonist (pioglitazone) on these parameters in obese glucose tolerant men. Arterial stiffness …